Akouos, Inc. (AKUS), relating to its proposed acquisition by Eli Lilly and Company. Under the terms of the tender offer, AKUS shareholders are expected to receive $12.50 in cash plus one CVR of up to $3.00 per share they own.
Akouos, Inc. (AKUS), relating to its proposed acquisition by Eli Lilly and Company. Under the terms of the tender offer, AKUS shareholders are expected to receive $12.50 in cash plus one CVR of up to $3.00 per share they own.